Annex (PI 28A)
PFIZER OPERATING PRINCIPLES FOR WORKING IN
PARTNERSHIP WITH PATIENT SUPPORT GROUPS
Pfizer is a global research-based healthcare
company. Our medicines span a wide array of therapy areas, and
all of them are designed with the goal of improving the quality
of people's lives.
Many stakeholders are of great importance in
ensuring the delivery of good quality cost-effective healthcare,
including healthcare providers, patient groups and political organisations.
We believe that Pfizer has an active and strong role to play in
the provision of healthcare, and as such in the need to build
close working relationships with all of our partners in healthcare.
The establishment of collaborative working relationships
between Pfizer and patient support groups (PSGs) can result in
real benefits for those affected by the disease or condition who
are represented by the PSG, especially where there are shared
objectives, common goals, and mutual benefits.
Support for PSGs can be provided through financial
sponsorship and/or donations to fund projects and/or core funding,
or through other benefits in kind, such as resources to support
internal and external communication, education and external policy
initiatives.
It is important that such partnerships and/or
collaborations are based on the understanding that all activities
should be conducted within a clearly understood and mutually accepted
set of key operating principles, in order to avoid both the reality
and/or the perception of improper or undue influence.
The purpose of this document is to outline our
own definition of these key principles, as guided by Pfizer values,
mission and culture.
Principles:
— There should be transparency at all
times in any activities between Pfizer and the PSG.
— Confidential information about members
of the PSG, individuals associated with it, or other confidential
information remains the property of the PSG and shall not be made
available to Pfizer.
— Parameters and timeframes should
be understood and agreed from the outset.
— Joint agreements or projects undertaken
between Pfizer and the PSG should be based on equal partnership
with mutual respect and trust.
— The PSG may offer information across
a range of products, but Pfizer must not demand the endorsement
of a single pharmaceutical product be it prescription-only or
OTC.
— No undue influence should be exerted
on the agenda, priorities or operations of the PSG.
— The independence of the internal
policy making, political judgement and activities of the PSG should
be assured at all times.
— Association with Pfizer should in
no way compromise, or be seen to compromise, the independence
of the PSG.
— Pfizer will at no time use the name
or logo of the PSG, or make any claim of association with the
PSG, without its prior written agreement, nor use any unauthorised
quote from a member of the PSG.
— The PSG should be consulted on and
retain ultimate editorial control over all materials produced
in their name and the use of their logo.
— Wherever necessary, Pfizer and PSG
should provide each other with copies of reports, accounts and
other appropriate information relating directly to the partnership
or collaboration, excluding any confidential information.
— Pfizer will always try to comply
with applicable rules and regulations governing their attendance
at, and participation in, PSG meetings.
— Pfizer will ensure that it respects
the independence of any of its employees actively engaged in PSG
work.
|
